Cogent Biosciences Inc (COGT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cogent Biosciences Inc (COGT) has a cash flow conversion efficiency ratio of -0.124x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-79.11 Million) by net assets ($636.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check Cogent Biosciences Inc (COGT) strategic asset index to assess the company's strategic physical and investment asset allocation.
Cogent Biosciences Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Cogent Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Cogent Biosciences Inc (COGT) shareholders funds for net asset value and shareholders' equity analysis.
Cogent Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cogent Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enel Chile SA ADR
NYSE:ENIC
|
0.098x |
|
NewJersey Resources Corporation
NYSE:NJR
|
0.212x |
|
BRF S.A
SA:BRFS3
|
0.142x |
|
APL Apollo Tubes Limited
NSE:APLAPOLLO
|
0.241x |
|
IMCD NV
AS:IMCD
|
0.105x |
|
Nestle (Malaysia) Bhd
KLSE:4707
|
0.479x |
|
Reinet Investments SCA
JSE:RNI
|
0.000x |
|
Black Hills Corporation
NYSE:BKH
|
0.044x |
Annual Cash Flow Conversion Efficiency for Cogent Biosciences Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Cogent Biosciences Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Cogent Biosciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $636.37 Million | $-264.44 Million | -0.416x | +48.75% |
| 2024-12-31 | $256.29 Million | $-207.79 Million | -0.811x | -36.06% |
| 2023-12-31 | $257.80 Million | $-153.62 Million | -0.596x | -28.45% |
| 2022-12-31 | $255.74 Million | $-118.64 Million | -0.464x | -69.09% |
| 2021-12-31 | $214.18 Million | $-58.76 Million | -0.274x | -79.59% |
| 2020-12-31 | $234.67 Million | $-35.85 Million | -0.153x | +88.31% |
| 2019-12-31 | $31.76 Million | $-41.51 Million | -1.307x | -142.32% |
| 2018-12-31 | $60.23 Million | $-32.49 Million | -0.539x | +40.91% |
| 2017-12-31 | $28.30 Million | $-25.84 Million | -0.913x | -156.53% |
| 2016-12-31 | $52.39 Million | $-18.64 Million | -0.356x | -239.62% |
| 2015-12-31 | $69.52 Million | $17.72 Million | 0.255x | -- |
About Cogent Biosciences Inc
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well… Read more